Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Daratumumab slows progression in refractory multiple myeloma

Prof Palumbo - University of Turin, Turin, Italy

$Daratumumab slows progression in refractory multiple myeloma ( Prof Palumbo - University of Turin, Turin, Italy )$

Developments in haematological malignancies

Dr Stephen Nimer - University of Miami, Miami, USA

Developments in haematological malignancies ( Dr Stephen Nimer - University of Miami, Miami, USA )

Recent developments in targeted therapies

Dr Stephen Nimer - University of Miami, Miami, USA

Recent developments in targeted therapies ( Dr Stephen Nimer - University of Miami, Miami, USA )

MyPathway guidance of targeted therapy based on molecular profiles

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Subset of anaplastic glioma patients benefit from adjuvant chemo

Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Subset of anaplastic glioma patients benefit from adjuvant chemo ( Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands )

Advanced RET-rearranged NSCLC

Dr Takashi Seto and Dr Kiyotaka Yoh

Advanced RET-rearranged NSCLC ( Dr Takashi Seto and Dr Kiyotaka Yoh )

Update on olaparib in ovarian cancer

Prof Jonathan Ledermann - University College Hospital Medical School, London, UK

Update on olaparib in ovarian cancer ( Prof Jonathan Ledermann - University College Hospital Medical School, London, UK )

CPX-351 improves outcomes for refractory AML

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

$CPX-351 improves outcomes for refractory AML ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )$

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational...

Prof Nick James and Prof Charles Ryan

ASCO 2016: Accuracy of multi-parametric MRI to predict further investigational biopsy ( Prof Nick James and Prof Charles Ryan )

First in-human trials of rovalpituzumab for SCLC

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

First in-human trials of rovalpituzumab for SCLC ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )

Phase I study of sapacitabine and seliciclib in patients with advanced solid...

Dr Sara Tolaney - Dana Farber Cancer Institute, Boston, USA

Phase I study of sapacitabine and seliciclib in patients with advanced solid tumours ( Dr Sara Tolaney - Dana Farber Cancer Institute, Boston, USA )

More from ecancer